Phase II" Proof of Concept " Trial Evaluating Anti Cancer Stem Cell Activity of Pre-operative Bevacizumab in Combination With Chemotherapy in Breast Cancer (AVASTEM)

NCT01190345 Phase 2 COMPLETED

The purpose of this study is to evaluate anti-cancer stem cell (CSC) activity (measured by the amount of Aldehyde dehydrogenase 1/ALDH1+ cells before and after treatment) of pre-operative bevacizumab in combination with conventional chemotherapy in breast cancer receiving neo-adjuvant treatment, compared to a control arm receiving chemotherapy alone.

Details

Lead sponsor	Institut Paoli-Calmettes
Phase	Phase 2
Status	COMPLETED
Enrolment	75
Start date	2010-05
Completion	2017-10-06

Conditions

• Breast Cancer

Interventions

• bevacizumab
• no bevacizumab

Primary outcomes

• Measure of the anti-cancer stem cell activity — 4 months
  The anti-cancer stem cell (CSC) activity is measured by the amount of Aldehyde dehydrogenase 1/ALDH1+ cells after 4 cycles of treatment compared to the amount before treatment

Countries

France